Nintedanib Newbury (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—that drive fibroblast activation, angiogenesis, and extracellular matrix production. By inhibiting these signaling pathways, the medication reduces the formation of fibrotic tissue in the lungs, helping to maintain lung capacity and limit disease advancement.

The exact dose of Nintedanib Newbury is determined by the prescribing clinician based on the patient’s condition, weight, liver function, and other individual factors. Healthcare providers follow the approved labeling and adjust the regimen as needed, so patients should follow the specific instructions given by their doctor.

The safety of Nintedanib in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and the drug should only be used if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nintedanib belongs to the tyrosine kinase inhibitor class, whereas the main alternative, pirfenidone, is a different antifibrotic agent that targets inflammatory pathways. Both drugs aim to slow lung function decline, but they differ in side‑effect profiles, drug‑interaction potential, and dosing schedules, making individual patient factors important in therapy selection.

Nintedanib Newbury tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the drug’s stability and potency throughout its shelf life.

The medication is taken orally, usually with food to lessen gastrointestinal discomfort. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their physician, without crushing or chewing the tablet unless otherwise directed.

Serious risks include significant liver enzyme elevations that may signal hepatic injury, severe bleeding events, and rare arterial thromboembolic complications. Patients should be monitored regularly for signs of liver dysfunction, unexpected bruising, or symptoms of vascular occlusion, and report any concerns promptly to their healthcare provider.

Nintedanib is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients, and it should be avoided in individuals with severe hepatic impairment. Additionally, patients who are pregnant, planning to become pregnant, or who are breastfeeding should not use the drug unless the prescriber determines that the benefits outweigh the potential risks.